Core Viewpoint - The recent research from the University of California, Berkeley, challenges the traditional belief that high-calorie foods are solely responsible for obesity, suggesting that the pleasure derived from eating can play a positive role in weight management [6]. Group 1: Research Findings - The study titled "Neurohypophyseal Signal Changes Drive Hedonic Devaluation in Obesity" reveals that the enjoyment experienced during eating can help maintain energy balance, redefining the relationship between food pleasure and obesity [6]. - High-fat diets were shown to impair the brain's reward system, leading to a decreased desire for high-calorie foods, despite weight gain in subjects [8][9]. - The research identified the neuropeptide NTS as a critical factor in this process, with high-fat diets significantly reducing its expression, which normally enhances dopamine neuron activity during food enjoyment [11]. Group 2: Implications for Weight Management - Restoring NTS levels through dietary intervention or gene therapy in obese mice resulted in a normal response to food, reduced overall food intake, and significant weight loss, suggesting a shift from appetite suppression to restoring the brain's reward mechanisms [12]. - This study opens new avenues for developing personalized treatments that allow individuals to enjoy food while managing their weight, potentially addressing broader metabolic diseases like diabetes and eating disorders [12].

以下文章来源于体重管理三年行动 ，作者体重管理三年行动 体重管理三年行动 . 响应国家"健康中国2030"战略，落实"体重管理年"三年行动，本账号发布权威资讯 ▍2025年最新标准体重对照表 很多人总为体重数字焦虑，尤其女性常认为"体重过百"就是肥胖，非得减至100斤以下才算瘦，却忽视了身高差异和整体健康状况。 让我们参考2025年最新标准体重对照表，你或许会发现——自己其实并不胖！ 若一位175cm的男性体重145斤，实际属于标准范围，完全不算肥胖。特别值得注意的是，这类标准表格并不适用于健身人群，因为他们体重普 遍较高但身材紧实。例如同样175cm的健身男性，即使体重达160斤，身材依然可能相当匀称而非肥胖。 对于163cm的女性而言，体重115斤其实仅是标准水平，而非超标。不应为追求"两位数体重"而牺牲健康。同理，这一标准也不适用于健身女 性，她们因肌肉含量高而体重偏大，但身材却往往更加紧致有型。 因此，判断身材是否肥胖，BMI值比单纯体重更具参考价值。 BMI计算公式为：体重(kg)÷身高(m)²。BMI超过24为超重，超过28则属肥胖。对照自身BMI值所在范围即可判断体型状况，不必盲目减重。体 重绝 ...

Core Viewpoint - The article discusses the ongoing patent dispute between Songlei and Conjupro Biotherapeutics, a subsidiary of CSPC Pharmaceutical Group, regarding the validity of a US patent held by Songlei, which is currently under review by the USPTO [1][3]. Group 1: Patent Dispute Details - On June 30, Songlei announced that it was informed on June 24 about Conjupro's request for a Post Grant Review at the USPTO, questioning the validity of specific claims in Songlei's US patent (Patent No: 12,234,236) [1]. - Conjupro's application for "Compound 10" is claimed to be structurally identical to Songlei's "Compound 1," with Songlei asserting that its patent application was submitted over three months prior to Conjupro's [1]. - As of the announcement, the review request is still under examination by the USPTO [1]. Group 2: Background and Implications - Songlei noted that it could not ascertain the specific reasons behind Conjupro's review request, but highlighted that Conjupro had previously sought global licensing discussions for the GLP-1R agonist Compound 1, which Songlei declined [3]. - The patent in question is based on proprietary technology developed by Songlei and is currently being utilized in the development of the candidate drug ASC30, with multiple related molecules protected under various patent systems [4]. - The USPTO officially granted the patent rights to Songlei on February 25, 2025, citing its innovation and non-obviousness compared to existing technologies [4].

Core Viewpoint - The recent study from Harvard University reveals that the effectiveness of low-carbohydrate diets (LCDs) for weight loss is significantly influenced by food quality rather than just carbohydrate quantity, challenging traditional beliefs about dieting [5][7][12]. Summary by Sections Low-Carbohydrate Diets and Weight Loss - Traditional views suggest that strict carbohydrate restriction leads to effective weight loss, but new research indicates that not all low-carb diets are beneficial; the quality of food consumed is crucial [5][7]. - A large-scale study involving over 12,000 participants shows that diets high in animal protein and refined fats yield limited weight loss and may even cause weight rebound [5][8]. Importance of Food Quality - The study emphasizes that a high-quality low-carb diet, which includes plant-based proteins, healthy fats, and whole grains, is more effective in maintaining weight than traditional low-carb diets [7][10]. - Those who prefer red meat and processed foods within a low-carb framework tend to experience greater weight gain compared to those on a standard diet, highlighting the importance of food choices [5][8]. Individual Variability in Diet Effectiveness - The effectiveness of plant-based low-carb diets varies based on initial body weight, with overweight individuals (BMI 25-30) benefiting the most from such diets [10][12]. - The research suggests that personalized dietary approaches are essential, as the impact of low-carb diets on weight management is not uniform across different body types [10][12]. Implications for Future Dietary Guidelines - The findings advocate for a shift in dietary recommendations, prioritizing the quality of nutrients over mere carbohydrate reduction, which could lead to healthier weight management strategies [8][12]. - The study's conclusions are expected to influence global dietary guidelines, promoting a more personalized and scientifically-backed approach to nutrition [12][13].

Core Viewpoint - The article emphasizes the importance of weight management as a critical aspect of public health, particularly in combating chronic non-communicable diseases in China, aligning with the "Healthy China 2030" strategy [3][4]. Group 1: Chronic Disease Prevention and Weight Management - The main risk factors affecting residents' health in China are chronic non-communicable diseases, closely linked to lifestyle habits, dietary structure, and exercise, particularly abnormal weight issues [3]. - The initiative will focus on three main areas: community involvement, knowledge dissemination, and personalized services for weight management [4][5][6]. Group 2: Weight Management Guidelines - Weight is a core indicator of nutrition and health, and both high and low weights can lead to health risks; thus, a preventive approach through balanced diet and regular exercise is essential [7]. - Maintaining an ideal weight significantly reduces the risk of various chronic diseases, making weight management a lifelong commitment [8]. - Regular monitoring of weight and body metrics is crucial, with the Body Mass Index (BMI) being the standard for assessing weight status [10][11]. Group 3: Dietary and Lifestyle Recommendations - Recommended dietary practices include choosing low-calorie, high-nutrition foods, limiting high-calorie items, and developing good eating habits [19]. - Regular physical activity is vital for weight management, with suggestions for integrating exercise into daily routines [20]. - Quality sleep and a positive mindset are important for maintaining a healthy weight, with adults advised to get 7-8 hours of sleep [21]. Group 4: Family Involvement in Weight Management - Weight management should involve the entire family, with each member taking responsibility for their health and supporting one another in adopting healthy lifestyles [23]. Group 5: Intervention and Treatment for Overweight and Obesity - Personalized weight loss goals should be set gradually, with specific recommendations for different BMI categories [24]. - Lifestyle interventions, medical treatments, and innovative management systems are essential for effective weight management [27].

Core Viewpoint - The article discusses the safety and side effects of GLP-1 receptor agonists (GLP-1RA) used in the treatment of type 2 diabetes and obesity, highlighting the importance of understanding potential risks associated with these medications [11][15]. Summary by Sections Side Effects of GLP-1RA - Common side effects of GLP-1RA include nausea, diarrhea, vomiting, constipation, abdominal pain, gastroenteritis, and gastroesophageal reflux disease, which tend to alleviate over time [2]. - Serious health issues may arise, such as increased risk of thyroid cancer, pancreatitis, gallstones, acute kidney injury, retinal damage, and increased heart rate [2]. Comparison of Semaglutide and Tirzepatide - Semaglutide shows good safety in diabetes treatment but can cause gastrointestinal issues, with 17% of patients reporting nausea even at low doses (0.5 mg) [3]. - In clinical trials, 12.2% and 6.4% of patients experienced diarrhea and vomiting, respectively, with a 4% discontinuation rate due to side effects [3]. - Approximately 80% of tirzepatide users report at least one side effect, primarily nausea, diarrhea, constipation, or vomiting, similar to semaglutide [5]. - In trials, 33% of patients on the highest dose of tirzepatide reported nausea, compared to 44% for semaglutide, with diarrhea rates at 23% for tirzepatide and 31% for semaglutide [5]. Safety Warnings and Contraindications - GLP-1RA medications carry a black box warning for potential increased risk of thyroid C-cell tumors, advising against use in patients with a history of medullary thyroid carcinoma or related family history [8]. - Patients with type 2 multiple endocrine neoplasia syndrome, severe allergies to GLP-1RA, or those experiencing pancreatitis should avoid these medications [9]. - Caution is advised for individuals with a history of pancreatitis, severe gastrointestinal diseases, children under 18, and patients with uremia [10]. GLP-1RA and Thyroid Cancer Risk - Animal studies suggest a link between GLP-1RA and the development of medullary thyroid carcinoma, but the association with non-medullary thyroid cancer remains controversial [11]. - Overemphasis on unproven thyroid cancer risks may prevent patients from benefiting from GLP-1RA therapy [11]. - The EMA Safety Committee found that existing evidence does not support a causal relationship between GLP-1RA and thyroid cancer, with randomized controlled trials showing lower incidence rates of thyroid cancer among users [15].

Core Viewpoint - The announcement highlights a significant collaboration between Federal Pharmaceutical and Novo Nordisk, focusing on the development of the drug UBT251, which targets multiple receptors for treating obesity and type 2 diabetes [2][4]. Group 1: Financial Aspects - Federal Pharmaceutical's subsidiary, Federal Biotechnology, received a prepayment of $180 million from Novo Nordisk, equivalent to approximately 1.293 billion RMB after Danish tax deductions [2]. - The collaboration agreement allows Federal Biotechnology to potentially receive a total of $200 million in prepayments and up to $1.8 billion in milestone payments based on the drug's development and commercialization progress [4]. Group 2: Drug Development and Rights - UBT251 is currently in clinical development and operates through a triple mechanism targeting GLP-1, GIP, and glucagon receptors, aimed at treating obesity, type 2 diabetes, and other metabolic diseases [4]. - Novo Nordisk will hold exclusive rights for the development, production, and commercialization of UBT251 globally, excluding Greater China, while Federal Biotechnology retains rights in the Greater China region [4].

Core Viewpoint - GIP (Gastric Inhibitory Polypeptide) plays a crucial role in insulin secretion and glucose metabolism, especially in the context of type 2 diabetes (T2D), where its function is often impaired. Recent studies highlight the significance of GIP in enhancing the efficacy of diabetes treatments, particularly through the development of dual receptor agonists like Tirzepatide [2][4]. Group 1: GIP and Its Role in Diabetes - GIP is secreted by intestinal K cells and, along with GLP-1, is classified as an incretin hormone that stimulates insulin secretion, helping to clear approximately 80% of glucose absorbed from food. In T2D patients, the function of incretins is nearly lost, making the restoration of this function vital for treatment [2]. - After oral glucose intake, GIP is responsible for about 44% of insulin secretion, while GLP-1 accounts for only 22% [2]. Group 2: Tirzepatide Overview - Tirzepatide is a modified peptide based on the GIP sequence and is recognized as a leading GLP-1/GIP dual receptor agonist. It has a half-life of 5 days, allowing for weekly administration [4]. - Clinical trials indicate that Tirzepatide outperforms GLP-1 single receptor agonists, such as Semaglutide, in controlling blood sugar and reducing weight [4]. Group 3: Efficacy of Tirzepatide - In the SURMOUNT-1 study, patients treated with Tirzepatide (5mg, 10mg, and 15mg) experienced significant weight loss of 15.4%, 19.9%, and 22.9% respectively, compared to a mere 2.1% in the placebo group over 176 weeks. Additionally, Tirzepatide reduced the risk of diabetes progression by 88% [6]. - The SURMOUNT-2 study confirmed that higher doses of Tirzepatide led to an average weight loss of 15.7% (15.6kg) in obese patients with T2D over 72 weeks, with 81.6% and 86.4% of patients in the 10mg and 15mg groups losing over 5% of their body weight, respectively [8]. - The SURMOUNT-3 trial showed a weight reduction of up to 26.6% after 12 weeks of lifestyle intervention and 72 weeks of Tirzepatide treatment [10]. - In the SURMOUNT-4 trial, participants lost an average of 26.0% of their body weight over 88 weeks, with a 21.1% reduction during the initial 36 weeks [11]. Group 4: Side Effects and Tolerability - Approximately 80% of Tirzepatide users report at least one side effect, primarily nausea, diarrhea, constipation, or vomiting, similar to those experienced with Semaglutide. Notably, 33% of patients on the highest dose of Tirzepatide reported nausea, compared to 44% for Semaglutide [12]. - Tirzepatide may have a lower frequency and milder symptoms of side effects compared to Semaglutide due to its dual action mechanism, which can mitigate some of the central nervous system-related side effects associated with GLP-1 [14].

Core Viewpoint - The article emphasizes the increasing focus on weight management in China, driven by national health strategies and a growing demand for weight management services across various demographics [5][9][19]. Group 1: National Initiatives and Trends - The National Health Commission highlighted weight management during the recent national congress, indicating a significant governmental focus on this issue [5]. - In 2024, 16 ministries will jointly launch a three-year "Weight Management Year" initiative, reflecting the urgency and importance of addressing weight issues in the population [5]. - The concept of weight management has gained popularity, with hospitals reporting a surge in demand for weight management clinics, particularly among younger individuals and children [5][9]. Group 2: Hospital Services and Patient Demographics - Hospitals like Zhejiang University Second Hospital have established multiple specialized clinics for weight management, including nutrition, pharmacotherapy, and surgical options [9]. - The number of patients visiting weight management clinics has doubled in recent years, with approximately 13,000 visits annually at Zhejiang University Second Hospital [9][10]. - A notable increase in young patients seeking weight management services has been observed, with many presenting additional health issues such as diabetes and high uric acid levels [10][11]. Group 3: Weight Management Approaches - Experts stress that weight management should be viewed as a long-term commitment rather than a quick fix, advocating for sustainable lifestyle changes [7][15]. - A realistic weight loss goal is to lose 4 pounds per month, with an ideal annual target of 10% to 20% of body weight [13]. - Quick weight loss methods often lead to unsustainable practices and rebound weight gain, highlighting the importance of gradual and consistent efforts [14][18]. Group 4: Challenges and Misconceptions - Many patients express unrealistic expectations regarding rapid weight loss, often asking how much weight they can lose in a week [6][12]. - The phenomenon of "weight regain" is common, with many individuals reverting to previous habits after initial success, underscoring the need for ongoing lifestyle management [18]. - The article dispels the myth of "lying down to lose weight," emphasizing that there are no shortcuts to effective weight management [20].

Core Viewpoint - The article discusses the development and clinical research of HRS9531, a GLP-1/GIP dual receptor agonist, highlighting its potential in treating obesity and type 2 diabetes mellitus (T2DM) as global rates of these conditions rise [2]. Group 1: Research Findings - Research 1: HRS9531 injection showed a significant average weight loss of 22.8% in the treatment group compared to 1.7% in the placebo group after 36 weeks, with a difference of 21.1% (P<0.0001) [6]. - Research 2: In a 52-week study, HRS9531 maintained an average weight loss of up to 18.0% at week 32, while the placebo group experienced a weight gain of 0.74% [11]. - Research 3: The oral version of HRS9531 demonstrated good tolerability and a weight loss of 3.8 kg in the 10 mg group after 28 days, compared to 1.6 kg in the placebo group [17]. Group 2: Safety and Tolerability - In the first study, the adverse event rate was 91.8% for the HRS9531 group, primarily involving mild gastrointestinal issues, with no patients discontinuing treatment [7]. - The second study reported adverse event rates between 75.5% to 91.8% across different dosage groups, with no new safety risks identified [12]. - The oral formulation showed a total adverse event rate of 62.5% in the single-dose phase and 84.4% in the multiple-dose phase, with no severe adverse events reported [17]. Group 3: Future Outlook - HRS9531 is positioned as a leading candidate in the clinical development of GLP-1/GIP dual receptor agonists in China, with significant potential for managing obesity and T2DM [19]. - The dosing strategy indicates that switching to a bi-weekly administration after achieving initial weight management goals can maintain efficacy and improve long-term adherence [20]. - The development of the oral formulation fills a gap in the domestic market for GLP-1/GIP agents, supporting its broader application in metabolic disease treatment [20].